

# HEXIMA LIMITED

## ASX ANNOUNCEMENT



13 October 2021

### HEXIMA TO PRESENT AT AUSBIOTECH

#### *Presentation to be made available*

MELBOURNE, AUSTRALIA (13 October 2021): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing pezadeftide (formerly HXP124), as a potential new prescription topical treatment for onychomycosis, announces that it will present at AusBiotech's "Australia Biotech Invest & Partnering Conference 2021".

AusBiotech is the leading Australian industry body representing and advocating for organisations doing business in and with the global life sciences economy. The "Australia Biotech Invest & Partnering Conference 2021" represents the preeminent opportunity for companies to present their technology and story to a network of potential international partners and investors.

Hexima's presentation is scheduled to begin at 2:05 PM on Tuesday 26 October 2021, with the Company to be represented by CEO & Managing Director Mr Michael Aldridge. Following the presentation, Mr Aldridge will also take part in a Q&A forum with representatives from other life sciences companies.

AusBiotech registrants and attendees will be able to view the presentation virtually and in person, and a recording of the presentation will be available on Hexima's website ([www.hexima.com.au](http://www.hexima.com.au)).

Hexima will file a copy of its presentation with ASX prior to its appearance.

**This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO**

#### ***Enquiries:***

Dr Nicole van der Weerden  
Chief Operating Officer  
[n.vanderweerden@hexima.com.au](mailto:n.vanderweerden@hexima.com.au)

***To join our email database and receive company announcements please [click here](#)***

#### **ABOUT HEXIMA**

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit [www.hexima.com.au](http://www.hexima.com.au). You can also find us on [Twitter](#) and [LinkedIn](#) or email us at [info@hexima.com.au](mailto:info@hexima.com.au).